57 results about "Serological assay" patented technology

The invention discloses a benign and malignant nodule grading evaluation system based on large model fusion ultrasonic imaging and thyroid gene markers, which can organically fuse non-invasive examination and serological detection, can simulate and diagnose multi-grade risk probability information provided by a gold standard, realizes similar risk grading estimation in a non-invasive mode, and has a wide application prospect. The thyroid nodule risk assessment method can provide visual explanation conforming to clinical logic based on comprehensive information of iconography and molecular biology, can significantly improve the accuracy of thyroid nodule risk assessment, can also effectively improve clinical decision-making efficiency and patient credibility, and has important clinical application prospects. The system comprises a data acquisition module, an ultrasonic image feature extraction module, a gene marker feature extraction module, a multi-modal fusion and hierarchical reasoning module and a generation module.

The invention relates to the technical field of markers, in particular to application of a biomarker for identifying acute stage and chronic stage of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers have obvious difference between acute and chronic brucellosis patients. The biomarkers can realize acute and chronic staging of brucellosis, are high in sensitivity and specificity, and have relatively good diagnosis efficiency. A novel molecular diagnosis tool is provided for acute and chronic staging of brucellosis, the problems that existing serological detection is low in specificity, and clinical staging cannot be accurately judged are solved, and wide application prospects are achieved.

The invention discloses a neutralizing swine monoclonal antibody pO18-40 and a neutralizing swine monoclonal antibody pO18-43 for foot and mouth disease virus type O. The amino acid sequences of a heavy chain variable region (VH) and a light chain variable region (VL) of the antibody pO18-40 are respectively as shown in SEQ ID No. 1 and SEQ ID No. 2; the amino acid sequences of VH and VL of the antibody pO18-43 are respectively as shown in SEQ ID No. 3 and SEQ ID No. 4. The antibody obtained by the invention is a full-swine-source antibody, can specifically neutralize the classical strain of the O-type foot-and-mouth disease virus, and can clearly distinguish the classical strain of the O / Cathay topological type from the variant strain of the O / Cathay topological type. A key antigen epitope recognized by the antibody is located at the 149th amino acid of a VP1 protein G-H ring, and the site is a key site of O / Cathay strain antigen variation and vaccine immune protection. The antibody provided by the invention provides an important tool and theoretical basis for serological detection of O-type FMDV, vaccine immune effect evaluation and optimal design of broad-spectrum vaccines.

The utility model provides a kind of adjustable spectrum shaking table belongs to medical diagnosis and detection technical field, the device includes tray, disposable test piece one, disposable test piece two, drive base and homogenizing plate, installation groove is opened in tray, several LED lamp beads are evenly distributed in installation groove, and clamping strip is symmetrically arranged and fixedly connected at installation groove slot mouth edge, drive base is set in tray lower end, and homogenizing plate is clamped on clamping strip, the device is according to the deficiency of existing disposable test piece, by setting LED lamp bead, homogenizing plate cooperate drive base, it can guarantee that the style of different viscosity has very good shaking effect, eliminate the intensity, angle difference of artificial shaking, improve result consistency, the device can be operated without professional training, can directly use marketable disposable test piece, support a variety of serological detection, equipment operation is simple, overall cost is lower, it is favorable to market promotion, with good market prospect before sale.

The invention discloses a biomarker for detecting venous thrombosis and application of the biomarker, and belongs to the technical field of molecular markers, the biomarker is ESM1, early diagnosis and positive prevention of venous thrombosis embolism can be achieved by monitoring the marker, and compared with a diagnosis method in the prior art, the biomarker has the advantages that the biomarker is simple and convenient to use. The marker provided by the invention is a plasma-derived biomarker, can avoid invasive diagnosis, is minimally invasive in sampling, is easy to detect, does not cause body injury, and does not need to use a large instrument. Meanwhile, the ESM1 and D-dimer combined detection improves the sensitivity and accuracy of the existing serological detection method (D-dimer detection) for judging thrombus, and can be used for early prevention and treatment effect evaluation of venous thrombosis.

The invention relates to the technical field of detection, and discloses a kit for detecting a PLA2R antibody in urine, which comprises a non-invasive urine sampling device, a pore plate detection module and a time-resolved fluorescence detection module, the non-invasive urine sampling device comprises a urine collecting cup, a collecting cup and a U-shaped siphon which are matched up and down; a spiral flow guide groove for guiding the collection cup is formed in the inner wall of the urine collection cup; the collecting cup is located at the bottom of the urine collecting cup, and scale marks are arranged on the side wall of the collecting cup; the inlet end of the U-shaped siphon is communicated with the side wall of the collecting cup and is higher than the bottom of the collecting cup, and the outlet end of the U-shaped siphon extends into the urine collecting cup. According to the kit, urine is used for replacing serum to serve as a PLA2R-IgG antibody detection sample, the problems that traditional serological detection cannot achieve real-time monitoring and is high in cost are solved through the simplified process of non-invasive sampling-time resolution detection, and a convenient solution can be provided for rapid screening of membranous nephropathy.

This invention proposes a random forest-based diagnostic method for Pneumocystis jirovecii pneumonia (PCP), comprising the following steps: collecting case data to form a raw dataset; cleaning and normalizing the feature encoding of the raw dataset; calculating the importance score of each feature based on three indices: permutation importance, Gini importance, and mutual information, converting it into a feature sampling probability distribution, and selecting features with sampling probabilities higher than a preset threshold; constructing a random forest model and training and optimizing it; validating the model performance using a test set and outputting the trained PCP diagnostic model; inputting standardized test samples into the diagnostic model and outputting diagnostic results. This invention solves the industry problems of intolerance to traditional invasive diagnoses, high false positive / false negative rates in routine serological tests, and insufficient generalization ability of existing machine learning models, providing non-invasive, efficient, and universal technical support for early PCP diagnosis, and is suitable for clinical application in medical institutions at all levels.

The invention provides application of a serine palmitoyl transferase small subunit A (SPTSSA) as a biomarker in preparation of a kit for early diagnosis and / or prognosis prediction of breast cancer, and belongs to the technical field of biomedicine. Through bioinformatics analysis, histological verification and serological detection, expression characteristics of the SPTSSA in the breast cancer and the relationship between the SPTSSA and a tumor microenvironment are systematically discussed, the potential application value of the SPTSSA as a breast cancer prognosis marker is evaluated, and a potential target spot is expected to be provided for individualized treatment of the breast cancer. The invention confirms that the SPTSSA is a novel breast cancer biomarker, has important significance for diagnosis, prognosis and treatment of breast cancer, and provides a theoretical basis for a treatment strategy of targeted SPTSSA.

The invention relates to the technical field of biological detection, in particular to a saliva RF-IgM rapid detection kit and application thereof, and the saliva RF-IgM rapid detection kit comprises a saliva pretreatment module, a signal amplification module and a result interpretation module. The invention provides an RF-IgM rapid detection method based on a saliva sample and application thereof, and solves the problems of invasiveness and time consumption of traditional serological detection. Technical difficulties in saliva detection, including the problems of insufficient sensitivity and high false negative rate caused by large IgM molecular weight and saliva mucoprotein interference, are solved. Non-invasive, rapid and convenient detection of rheumatoid factors is achieved, patient compliance is improved, and the kit is suitable for outpatient real-time detection (POCT), primary medical treatment and large-scale population early screening.

The invention discloses an F1 monoclonal antibody and application thereof, the F1 monoclonal antibody is used for specifically binding a 6HB structural domain in a spike protein S2 subunit of SARS-CoV-2, the F1 monoclonal antibody comprises VHCDR1-3 of a heavy chain variable region and VLCDR1-3 of a light chain variable region, the amino acid sequences of the VHCDR1, the VHCDR2 and the VHCDR3 are respectively shown as SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the amino acid sequences of the VLCDR1, the VLCDR2 and the VLCDR3 are respectively shown as SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The invention further discloses an application of the F1 monoclonal antibody. The F1 monoclonal antibody can neutralize SARS-CoV-2 virus infection, and has important application value in serological detection of new coronavirus, preparation of a reagent for new coronavirus infection detection and a reagent for new coronavirus antigen or antibody detection.

This disclosure provides a novel serological method for detecting zoonotic viral infections, such as porcine cytomegalovirus (PCMV) infection or porcine lymphotropic herpesvirus (PLHV) infection, in subjects at any stage of disease development. More specifically, this disclosure provides an automated multiplexed immunoassay for the rapid and simultaneous detection of one or more anti-PCMV antibodies or anti-PLHV antibodies in the biological fluid of subjects suspected of being infected with PCMV or PLHV.

This disclosure relates to coronavirus assays, diagnostic methods, treatment methods, and compositions related thereto. In certain embodiments, this disclosure relates to ACE2 receptor binding domain peptides and uses in serological assays and vaccination methods.

The invention provides application of a biomarker in serum detected by a Raman spectrum in preparation of a product for predicting or detecting non-Hodgkin lymphoma, and belongs to the technical field of medical diagnosis. A spectroscopy basis is provided for mass serological detection data of a patient and early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma, and important information is provided for rapid early identification of the lymphoplasmal cell lymphoma and the diffuse large B-cell lymphoma.

A polynucleotide, a kit, an isothermal detection method and a method for predicting premature birth, the method for predicting premature birth comprising: analyzing the expression profile of any one or at least two gene sets in a maternal sample, and predicting whether the subject will have premature birth according to the expression profile. The present application detects the expression amount of the marker gene in the serum of pregnant women for the first time, which is used for the prediction of premature birth risk of pregnant women without clinical symptoms. The main advantage is serological detection, no need to make an appointment in advance like ultrasound, non-invasive detection, no need for vaginal or cervical sampling, and good detection process experience.

This disclosure relates to coronavirus assays, diagnostic methods, treatment methods, and compositions related thereto. In certain embodiments, this disclosure relates to ACE2 receptor binding domain peptides and uses in serological assays and vaccination methods.

The application discloses a broad-spectrum neutralizing pig-derived monoclonal antibody of type A foot-and-mouth disease virus (FMDV) and application thereof. The antibody PAF56 has an amino acid sequence of a heavy chain variable region as shown in SEQ ID No. 12, a heavy chain CDR1 sequence of GFGFSNTY, a heavy chain CDR2 sequence of VFTGGGAT, and a heavy chain CDR3 sequence of VSNRDGFGGVGNV. The antibody PAF56 has an amino acid sequence of a light chain variable region as shown in SEQ ID No. 13, a light chain CDR1 sequence of SGSVTSLNY, a light chain CDR2 sequence of RTN, and a light chain CDR3 sequence of ALYKGSGTDTNI. The antibody PAF56 can simultaneously neutralize an AF72 strain of an A22 lineage and A / WH / CHA / 09 and A / GDMM / 2013 epidemic strains of a domestic SEA97 lineage, and has broad-spectrum neutralization activity of type A FMDV. The antibody PAF56 recognizes an antigen site 2 of a VP2 B-C loop, and a key amino acid is VP2 D72; the recognized site is highly conserved in type A FMDV. The application first obtains a broad-spectrum neutralizing antibody of type A specific FMDV from a natural host and identifies a key antigen site recognized by the antibody, thereby providing a powerful tool for antigen structure analysis of FMDV and establishment of a serological detection method.

The invention discloses a double-enzyme lock activated photoacoustic probe for accurate imaging of drug-induced liver injury, a preparation method and application, the probe is named as SH-NAL, and the probe takes a sulfo-hemicyanine derivative SH-NH2 as a photoacoustic signal report group and a pseudo-peptide group as a recognition unit. A photoacoustic signal activation mechanism depends on a sequential enzyme digestion reaction of two DILI-related peptidases, and compared with single-enzyme response probes SH-NL and SH-NA, the photoacoustic signal activation mechanism has the advantage that the signal-to-noise ratio is remarkably improved. In in-vivo DILI photoacoustic imaging, the activation efficiency of the SH-NAL is far higher than that of a single lock type probe. Quantitative photoacoustic signal analysis is carried out in living animal imaging experiments and serological detection, SH-NAL can effectively distinguish DILI from liver cirrhosis, hepatitis and healthy liver tissue, and the double-enzyme lock activation strategy not only improves the diagnosis specificity, but also is expected to become a multifunctional platform for clinical research of DILI pathogenesis.

The invention relates to the field of medical detection, and particularly discloses a melanoma prognosis biomarker and application thereof. According to the multi-factor prediction model based on serological detection, GGCT is combined with lactic dehydrogenase (LDH), S100B protein and other biomarkers, and the prognosis risk of a melanoma patient can be accurately predicted. The content of GGCT in serum of a patient is detected through methods such as enzyme-linked immunosorbent assay (ELISA) and the like, comprehensive analysis is carried out in combination with other indexes, the area under a working characteristic curve (AUC) of a subject higher than 85% can be obtained, and high sensitivity and specificity are achieved. Compared with an existing single marker, the prediction effectiveness of the multi-factor model is remarkably improved, patients with high recurrence and metastasis risks can be recognized in the early stage, and individualized treatment is guided. The detection method is simple, convenient and rapid to operate, low in cost of required reagents, good in repeatability and stability and suitable for clinical popularization and application.

The application relates to the technical field of markers, in particular to application of biomarkers for identifying acute and chronic stages of brucellosis. A series of biomarkers related to acute and chronic stages of brucellosis are screened and found, and the biomarkers are significantly different between patients with acute and chronic brucellosis. The biomarkers can be used to realize acute and chronic staging of brucellosis, and have high sensitivity and specificity and good diagnostic efficiency. The application provides a new molecular diagnostic tool for acute and chronic staging of brucellosis, solves the problems of low specificity of existing serological detection and incapability of accurately judging clinical stages, and has a wide application prospect.

The invention discloses a hybridoma cell strain based on type 1 goose astrovirus, a construction method, a monoclonal antibody and a detection reagent. The hybridoma cell strain is a hybridoma cell strain A5A1, the preservation number of the hybridoma cell strain is CCTCC (China Center for Type Culture Collection) NO: C202505, and the hybridoma cell strain is preserved in the China Center for Type Culture Collection on March 26, 2025. According to the invention, a mouse is immunized by GAstV-1ORF2 recombinant protein expressed by a prokaryotic expression system, and a monoclonal antibody A5A1 is obtained by screening and subcloning. Indirect competitive ELISA (icELISA) for detecting the GAstV-1 antibody is developed based on the hybridoma cell strain A5A1, and the method is high in sensitivity, good in repeatability and high in specificity, only reacts with serum of GAstV-1, and does not have cross reaction with other detected pathogenic serum. A serological detection method established by the monoclonal antibody prepared by the method lays a foundation for scientific prevention and control of gout of goslings.

The invention discloses a novel anti-echinococcus monoclonal antibody, a hybridoma cell strain and application of the novel anti-echinococcus monoclonal antibody, and belongs to the technical field of biomedicine and immunology. The preservation number of the hybridoma cell strain Anti-Em-11 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 46598. According to the present invention, the specific monoclonal antibody is successfully prepared and identified, and Western blot and indirect immunofluorescence experiments prove that the obtained monoclonal antibody has high specificity on the recombinant protein. The invention lays a solid foundation for serological diagnosis of the echinococcosis and remarkably enriches the existing serological detection technical system.

The invention discloses an HBV infected mouse model and a construction method and application thereof, and the construction method comprises the following steps: step 1, taking a healthy female HBV-Tg mouse with a positive HBV marker as a liver donor, taking out the liver through an operation, and cutting the liver into small blocks; step 2, taking a healthy female NPG mouse with severe combined immunodeficiency as a receptor animal, pulling the maximum leaf of the liver to the outside of the abdominal cavity through an operation, placing a liver tissue block of the HBV-Tg mouse on the exposed liver parenchyma surface of the NPG mouse, performing auxiliary fixation, then returning the liver back to the abdominal cavity, and then suturing; 3, the copy number of HBV DNA in NPG mouse serum is measured, and if the two continuous detection values are remarkably higher than the background value and the index can be continuously maintained at a certain level in the subsequent observation period, the HBV infected mouse model is successfully constructed. According to the invention, the process from donor sampling to receptor transplantation can be completed within several hours, and the model can be verified through serological detection 1-2 weeks after operation, so that the modeling period is greatly shortened.

A system or method for a combination assay of human antibodies to Mycobacterium avium subsp. paratuberculosis (MAP) and cytokines for the diagnosis of Crohn's disease, tuberculosis, and other bacterial diseases in symptomatic and asymptomatic individuals is provided herein. The system or method describes generally using a combination of human antibodies to MAP useful for the detection of a MAP infection in human blood samples and cytokines secreted by the human host with a MAP infection to provide a simple and rapid serological test which can diagnose patients with Crohn's disease and can aid in the selection of patients for certain antibiotic therapies. A similar system could be used for the diagnosis and selection for therapy of tuberculosis and other mycobacterial or bacterial diseases.

The present disclosure provides a novel serological method for detecting viremia or a latent human-livestock co-occurrence virus infection (e.g., porcine cytomegalovirus (PCMV) or porcine lymphotropic herpesvirus (PLHV) infection) in a subject at any stage of development. More specifically, the present disclosure provides automated multiplex immunoassays for the rapid and simultaneous detection of one or more anti-PCMV or anti-PLHV antibodies in a biological fluid of a subject suspected of being infected with PCMV or PLHV.

The invention discloses a method and system for correcting two-dimensional ultrasonic image video data of autoimmune hepatitis cirrhosis, and relates to the technical field of data processing, and the method comprises the following steps: obtaining two-dimensional ultrasonic image video original data and corresponding clinical diagnosis data of a patient with autoimmune hepatitis cirrhosis; performing classification extraction on the original data and the clinical diagnosis data to obtain dynamic image sequence data, ultrasonic characteristic parameter data, hepatic fibrosis grading data and serological detection data; based on the dynamic image sequence data, judging texture consistency, contour integrity and motion artifact interference degree of images at different time nodes to determine a quality evaluation result of the image sequence; based on the ultrasonic characteristic parameter data, multiple groups of parameter measurement results of the same detection part are compared, so that the typical ultrasonic characteristics of different lesion stages are effectively presented, the early cirrhosis identification accuracy and the curative effect monitoring precision are greatly improved, and the missed diagnosis and misdiagnosis risks are reduced.

The invention provides a prevention and control method for cynomolgus monkeys based on SRV virus detection, and belongs to the technical field of cynomolgus monkey SRV virus detection, the cynomolgus monkeys after birth are subjected to intensive SRV antigen PCR and SRV antibody ELISA detection and are fed and managed in groups, negative animals after 9 months are subjected to annual quarantine, positive animals stop quarantine and are subjected to positive management by default, and the cynomolgus monkeys after birth are subjected to SRV antigen PCR detection and SRV antibody ELISA detection by default. The antibody positive and / or antigen positive belongs to the positive category. According to the method, SRV antigen PCR and SRV antibody ELISA detection are densely carried out on the cynomolgus monkeys after birth, grouping feeding management is carried out, early prevention and control can cut off a transmission chain, recessive infection can be effectively recognized, partially-infected monkeys are low in antibody reaction and even cannot be detected, but long-term detoxification can be achieved, recessive infection sources can be accurately removed by combining PCR and serological detection in the baby monkey period, and the method has the advantages of high specificity, high sensitivity, high sensitivity and the like. Although the detection cost is invested in the early stage, huge losses such as treatment, animal elimination and experiment repetition caused by disease outbreak in the future can be avoided.

The invention provides ECM1 as a marker for serological detection of liver injury and application of the ECM1. Specifically, the invention provides liver injury evaluation equipment which comprises an input module, a processing module and an output module. According to the liver injury assessment equipment, various liver injury risks can be accurately judged according to the concentration of the input liver injury biomarker ECM1.

The invention discloses a diagnostic antigen of a goat pox virus (GTPV), and belongs to the field of molecular biology. The diagnostic antigen of the goat pox virus (GTPV) belongs to the field of molecular biology. A nucleotide sequence of a coding gene of the antigen is shown as SEQ ID NO.1. The antigen protein has immunogenicity, can be used for immunizing animals to generate a monoclonal antibody with good activity, and can react with GTPV immune serum, so that the antigen protein can be used for serological detection and vaccine immune evaluation of GTPV. The invention also discloses a monoclonal antibody for resisting the antigen, and an application of the antigen and / or the monoclonal antibody in preparation of a GTPV diagnostic kit. According to the invention, GTPV detection of goatpox virus is realized, and the kit has the advantages of high sensitivity and specificity, rapid and convenient detection and the like.

The invention relates to a protease treatment reagent and application thereof in enzyme treatment of cells, and the protease treatment reagent is prepared by the following steps: adding L-cysteine, Pluronic, gelatin, a chelating agent and a bacteriostatic agent into a buffer agent, dissolving at room temperature, and obtaining the protease treatment reagent after complete dissolution; the protease treatment reagent is used as a grinding reagent to fully grind protease, the protease treatment reagent is used for fixing the volume, then a microporous filter is used for filtering to obtain a protease solution, and the obtained protease solution is used for treating red blood cells and further used for red blood cell blood group serological detection. The protease treatment reagent has a stable pH buffer environment, the protease activity can be effectively protected, the protease is pretreated by the protease treatment reagent to form a protease solution, and the protease solution can be stably stored for a long time; an original enzyme treatment cell method is converted into a unified, controllable and standardized enzyme treatment cell production mode from a laboratory method, and the utilization rate of protease and the success rate of enzyme treatment cells are greatly improved.

The invention discloses a serum pre-embedding method and application thereof. The serum pre-embedding method comprises the following steps: (1) performing centrifugal clarification on serum, removing impurities, and filtering and sterilizing supernate; (2) adding a protective agent into the degermed serum, and filtering and degerming the protective agent to ensure that the serum is sterile; and (3) dropwise adding the serum containing the protective agent into the detection holes of the detection plate, dehydrating and drying in a normal-pressure environment at 35-38 DEG C, and after water in the serum is evaporated, retaining and adsorbing active ingredients into the plate holes. The serum is pre-buried in holes of the detection plate through normal-pressure drying at the temperature of 35-38 DEG C, the steps of dropwise adding and uniformly mixing the serum in the detection process are omitted, the detection process becomes simpler and faster, the detection efficiency is greatly improved during multiple detection of multiple samples, and serological detection can be used for high-throughput multiple detection of the samples; and the pre-embedding method adopted by the invention is simple to operate, does not need expensive equipment, needs low energy consumption in the pre-embedding process, and has a good market application prospect.